Back to Rankings

IDYA

IDEAYA BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart

AI scenario view

RankAlpha Sentiment AI
B+
Bull case
20%
Probability
Target price
$79.00
+183.5% vs current
Most likely
B
Base case
60%
Probability
Target price
$49.00
+75.8% vs current
B-
Bear case
20%
Probability
Target price
$25.00
-10.3% vs current

AI sentiment snapshot

Latest data as of 2026-01-08
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score

AI commentary

Sell­-side consensus averages sit above the current anchor, supporting a constructive stance, but wide dispersion (low­-$30s to high­-$70s) indicates binary clinical outcomes. Near­-term sentiment is event­-driven: positive readouts or partnership news would likely push the stock toward base/bull targets, while negative data or financing pressure would compress it toward the bear target.

RankAlpha Sentiment AI - 2026-01-08
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-04-08catalystPartnership or licensing announcementHigh impact

Potential business-development deal or licensing collaboration that could de-risk programs and expand cash runway; market consensus and analyst attention increase deal odds [#SERP-1].

2026-06-30eventClinical readouts for lead oncology programsHigh impact

Mid-stage clinical readouts for IDEAYA's lead oncology programs; timing and outcome will materially move valuation (consensus analyst coverage noted) [#SERP-2]. Assumed window end used for date selection.

2027-01-08catalystCommercial adoption / late-stage success scenarioHigh impact

If clinical success is sustained and regulatory path clears, broader commercialization could materially re-rate shares over the long term; consensus 12­-month analyst targets provide a reference band [#SERP-3].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-01-08 • Updated nightlySource: Internal modelMethodology